Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06162663 · ClinicalTrials.gov registry record · Phase 4
Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors
A Phase 4 study, sponsored by Medical University of South Carolina.
- Terminated
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT06162663 is a Phase 4 study that was terminated before completion, run by Medical University of South Carolina. The registered enrollment target is 5 participants.
The verdict
NCT06162663, a Phase 4 study, was terminated before completion, sponsored by Medical University of South Carolina.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
Investigators propose a double-blind, placebo-controlled trial evaluating the use of the use of Suvorexant in breast cancer survivors on selective estrogen receptor modulators or aromatase inhibitors with sleep disturbance to assess the impact on insomnia symptoms and quality of life. Breast cancer survivors have an increased risk of insomnia for which Suvorexant has the has the potential ability to impact to improve sleep related outcomes and cancer survivorship outcomes. Breast cancer survivors with sleep disturbance based on an Insomnia Severity Index Score (ISI) \>15 will be randomized to either Suvorexant or placebo, with both arms receiving education on sleep hygiene.
Interventions
- OTHER Placebo Control
- DRUG Suvorexant Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2024-09-20 |
| Est. Completion | 2026-02-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06162663
The ClinicalTrials.gov registry entry for NCT06162663 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Control is the first listed.
NCT06162663 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06162663 about?
NCT06162663 is a clinical study titled "Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors". Investigators propose a double-blind, placebo-controlled trial evaluating the use of the use of Suvorexant in breast cancer survivors on selective estrogen receptor modulators or aromatase inhibitors with sleep disturbance to assess the impact on insomnia symptoms and quality of life. Breast cancer ...
What is the current status of trial NCT06162663?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2024-09-20. Estimated completion is 2026-02-17.
What interventions are being tested in trial NCT06162663?
The interventions under investigation include: Placebo Control (OTHER), Suvorexant Tablets (DRUG).
Who is sponsoring clinical trial NCT06162663?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.